[212Pb]VMT-alpha-NET
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for [212Pb]VMT-alpha-NET, covering 2025-11-04 to 2026-03-10. Get the full timeline:
Most recent: Clinical Trial Update: Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy [Phase 1, Phase 2]